Award,contract · Find a Tender
Pathology Managed Services Framework
Part of Pathology Managed Services Framework.
The Royal Wolverhampton NHS Trust is seeking to create a framework for Pathology Managed Services. It is intended that the framework will be in place for 48 months. RWT will expect appointed suppliers to work closely and proactively with contracting authorities to create collaborative working relationships which deliver cost savings, efficiencies and improvements to patient care.
- Procurement
- Pathology Managed Services Framework
- Published
- 3 Feb 2023
- Status
- complete
- CPV
- 85111800 — Pathology services
- Tender period
- —
Awards
- Abbott Laboratories Limitedactive—
- Arkray Limitedactive—
- Beckman Coulter United Kingdom Limitedactive—
- Becton Dickinson U.K. Limitedactive—
- BioMerieux UK Limitedactive—
- Diagnostica Stago UK Ltdactive—
- Genmed.me Limitedactive—
- Grifols UK Ltdactive—
- Launch Diagnostics Ltdactive—
- Leica Microsystems UK Limitedactive—
- Ortho Clinical Diagnosticsactive—
- Roche Diagnostics Limitedactive—
- Siemens Healthcare Limitedactive—
- Sysmex UK Ltdactive—
- The Binding Site Group Limitedactive—
- Werfen Ltdactive—
- Abbott Laboratories Limitedactive—
- Sysmex UK Ltdactive—
- Werfen Ltdactive—
- Abbott Laboratories Limitedactive—
- Beckman Coulter United Kingdom Limitedactive—
- bioMerieux UK Limitedactive—
- Roche Diagnostics Limitedactive—
- Siemens Healthcare Limitedactive—
- Leica Microsystems UK Limitedactive—
Other notices in this procurement
FAQs about this notice
What type of notice is this?
This is a award,contract published via Find a Tender on 3 Feb 2023.
Which procurement does this notice belong to?
It is part of "Pathology Managed Services Framework", published by The Royal Wolverhampton NHS Trust.
Has this notice resulted in an award?
25 awards are recorded on this notice, including to Abbott Laboratories Limited.
Get the full procurement picture
Enable turns the UK's public-contract data into pipeline intelligence for bid and capture teams. Talk to us about access, alerts and tailored market analysis.
Get in touch with Enable